3 assets in Neoplasm With Perivascular Epithelioid Cell Differentiation

Therapeutic assets addressing Neoplasm With Perivascular Epithelioid Cell Differentiation, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Neoplasm With Perivascular Epithelioid Cell Differentiation	Sarcoma Oncology Research Center, LLC	P2	B (62)
Ipilimumab Neoplasm With Perivascular Epithelioid Cell Differentiation	National Cancer Institute (NCI)	P2	CCC (53)
Ivocizumab Neoplasm With Perivascular Epithelioid Cell Differentiation	Fudan University	P2	NR ()